This document lists the medicines eligible for supply through the Northern Ireland MHRA Authorised Route (NIMAR).
From 1 January 2022, the listed medicines may be dispatched from Great Britain to Northern Ireland on the basis of the medicines authorisation in Great Britain.
This list is maintained and published in accordance with regulation 167B (list of NIMAR products) of the Human Medicines Regulations 2012 (SI 2012/1916, as amended).
Published 16 December 2021 Last updated 17 March 2023 +show all updates
Added: (Byetta 10micrograms/0.04ml solution for injection 2.4ml pre-filled pens) Exenatide 10micrograms/0.04ml solution for injection 2.4ml pre-filled disposable devices; (Byetta 5micrograms/0.02ml solution for injection 1.2ml pre-filled pens) Exenatide 5micrograms/0.02ml solution for injection 1.2ml pre-filled disposable devices; Hydroxycarbamide 100mg tablets.
Added: Avalglucosidase alfa 100mg powder for solution for infusion vials; Etoposide 100mg/5ml solution for infusion vials.Removed: (Truxima 500mg/50ml concentrate for solution for infusion vials) Rituximab 500mg/50ml solution for infusion vials.
Added: Canagliflozin 100mg tablets and Canagliflozin 300mg tablets. Removed (Toujeo 300units/ml solution for injection 3ml pre-filled DoubleStar pens) Insulin glargine 300units/ml solution for injection 3ml pre-filled disposable devices; Upadacitinib 45mg modified-release tablets; and (Plavix 75mg tablets) Clopidogrel 75mg tablets.
Updated to add (Plavix 75mg tablets) Clopidogrel 75mg tablets.
Removed from the list: Patisiran 2 mg/ml concentrate for solution for infusion. Added to the list: Methotrexate 1g/10ml solution for injection vials and Methotrexate 5g/50ml solution for infusion vials.
Updated to add 'Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) dispersion for injection' and to remove 'Cell-based quadrivalent influenza vaccine (surface antigen, inactivated) suspension for injection 0.5ml pre-filled syringes'.
The following medicine has been added to the list: (Toujeo 300units/ml solution for injection 3ml pre-filled DoubleStar pens) Insulin glargine 300units/ml solution for injection 3ml pre-filled disposable devices, and the following 6 medicines have been removed from the list: (HyQvia 10g/100ml solution for infusion and 5ml vials) Normal immunoglobulin human 10g/100ml solution for infusion vials and Recombinant human hyaluronidase solution for infusion 5ml vials, (HyQvia 2.5g/25ml solution for infusion and 1.25ml vials) Normal immunoglobulin human 2.5g/25ml solution for infusion vials and Recombinant human hyaluronidase solution for infusion 1.25ml vials, (HyQvia 30g/300ml solution for infusion and 15ml vials) Normal immunoglobulin human 30g/300ml solution for infusion vials and Recombinant human hyaluronidase solution for infusion 15ml vials, (HyQvia 5g/50ml solution for infusion and 2.5ml vials) Normal immunoglobulin human 5g/50ml solution for infusion vials and Recombinant human hyaluronidase solution for infusion 2.5ml vials, (Fotivda 1340microgram capsules) Tivozanib 1340microgram capsules, and (Fotivda 890microgram capsules) Tivozanib 890microgram capsules.
Changed '(Esperoct 5000 unit powder and solvent for solution for injection vials) Turoctocog alfa pegol 500 unit powder and solvent for solution for injection vials' to: '(Esperoct 500 unit powder and solvent for solution for injection vials) Turoctocog alfa pegol 500 unit powder and solvent for solution for injection vials'. Added the following medicines to the list: Ibandronic acid 50mg tablets; Lixisenatide 20mg / 0.2ml solution for injection 3ml pre-filled disposable devices; Potassium citrate 282mg / Potassium bicarbonate 527mg modified-release granules sachets sugar free; and Potassium citrate 847mg / Potassium bicarbonate 1.582g modified-release granules sachets sugar free.
28 products have been added to the list: Normal immunoglobulin human 2.5g/25ml solution for infusion vials and Recombinant human hyaluronidase solution for infusion 1.25ml vials;Normal immunoglobulin human 5g/50ml solution for infusion vials and Recombinant human hyaluronidase solution for infusion 2.5ml vials;Normal immunoglobulin human 10g/100ml solution for infusion vials and Recombinant human hyaluronidase solution for infusion 5ml vials;Normal immunoglobulin human 30g/300ml solution for infusion vials and Recombinant human hyaluronidase solution for infusion 15ml vials;Naloxone 1.8mg/0.1ml nasal spray unit dose;Glycopyrronium 7.2micrograms/dose / Formoterol 5micrograms/dose inhaler CFC free;Interferon beta-1b 300microgram powder and solvent for solution for injection vials;Saxagliptin 2.5mg / Metformin 1g tablets;Saxagliptin 5mg / Dapagliflozin 10mg tablets;Eptacog alfa (activated) 1mg (50,000unit) powder and solvent for solution for injection pre-filled syringes;Eptacog alfa (a
